Michael Barbella, Managing Editor06.22.23
MedX Health Corp.'s Board of Directors is undergoing a few changes.
Two new members have recently joined the governing body—Stephen Lockyer and Ed Ho, both of whom have many years of wide-ranging business and entrepreneurial experience. Lockyer is president and owner of Nova Scotia-based Armshore Investments Limited, a venture capital investor in real estate and early-stage technology companies. Ho, a chartered financial analyst, has years of experience as a portfolio manager with a major mutual fund covering diverse mandates, including venture capital, tax strategies, and management of both small-cap and large-cap investment funds.
Besides the addition of Lockyer and Ho, the board has appointed David Hennigar—a director since 2001—as vice chairman. Moreover, Director Wayne Cockburn has retired from the board after a two-and-a-half-year tenure.
“The Board looks forward to the invaluable expertise and counsel that both Mr. Lockyer and Mr. Ho will bring to the company, especially at a point where MedX’s SIAscopy technology and DermSecure platform are being launched widely across Canada. We also wish to thank Mr. Cockburn for his service since he joined the Board in October 2020,” MedX Chairman Ken McKay said.
Headquartered in Ontario, Canada, MedX is a medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil, and Turkey.
Two new members have recently joined the governing body—Stephen Lockyer and Ed Ho, both of whom have many years of wide-ranging business and entrepreneurial experience. Lockyer is president and owner of Nova Scotia-based Armshore Investments Limited, a venture capital investor in real estate and early-stage technology companies. Ho, a chartered financial analyst, has years of experience as a portfolio manager with a major mutual fund covering diverse mandates, including venture capital, tax strategies, and management of both small-cap and large-cap investment funds.
Besides the addition of Lockyer and Ho, the board has appointed David Hennigar—a director since 2001—as vice chairman. Moreover, Director Wayne Cockburn has retired from the board after a two-and-a-half-year tenure.
“The Board looks forward to the invaluable expertise and counsel that both Mr. Lockyer and Mr. Ho will bring to the company, especially at a point where MedX’s SIAscopy technology and DermSecure platform are being launched widely across Canada. We also wish to thank Mr. Cockburn for his service since he joined the Board in October 2020,” MedX Chairman Ken McKay said.
Headquartered in Ontario, Canada, MedX is a medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil, and Turkey.